J7Z:FRA
Jazz Pharmaceuticals PLC
€204.50
0.00%
(0.00) 1D
Oct 1, 8:10:03 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for J7Z...
Open
€204.50
High
€204.50
Low
€204.50
Mkt. cap
15.03B
Avg. vol.
1.00
Volume
0.00
52-wk high
€229.50
52-wk low
€108.55
No. of employees
3K
Open
€204.50
High
€204.50
Low
€204.50
Mkt. cap
15.03B
Avg. vol.
1.00
Volume
0.00
52-wk high
€229.50
52-wk low
€108.55
No. of employees
3K
News stories
From web sources and news partners
Profile
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC
CEOBruce C Cozadd
Employees2.89K
Founded2003
Headquarters-
SectorPharmaceutical industry
Websitejazzpharma.com